Adding Talazoparib to Treatment for Androgen Pathway Modulation–Sensitive Metastatic Prostate Cancer

Patients with advanced prostate cancer who have homologous recombination repair (HRR) mutations, especially those with BRCA 1 or 2 alterations, have worse outcomes. The AMPLITUDE phase III study demonstrated that poly(ADP-ribose) polymerase (PARP) inhibitors improve progression-free survival (PFS) in patients with androgen pathway modulation–sensitive (APMS) metastatic prostate cancer. Now, researchers report the findings of the international, randomized TALAPRO-3 trial, in which almost 600 patients with metastatic APMS and HRR alterations received either the PARP inhibitor talazoparib or placebo. All patients also received androgen deprivation therapy (ADT) and the androgen receptor pathway inhibitor enzalutamide. Of enrolled patien…